H19 Overexpression Linked to Leukemia Drug Resistance
Researchers have identified H19 lncRNA upregulation in myeloid leukemia cells resistant to azacitidine.
Updated on Sept. 21, 2026 in Cancer
Scientists have determined that prolonged exposure to azacitidine in myeloid leukemia cells leads to H19 overexpression. This epigenetic change reflects the cellular reprogramming that occurs as cancer cells develop resistance to treatment.
Why it matters
Understanding the mechanisms behind drug resistance is vital for improving outcomes in acute myeloid leukemia. While H19 is upregulated in resistant cells, it does not appear to be the direct driver of drug sensitivity changes.
RNA sequencing confirmed H19 upregulation in both resistant K562 cells and resistant HEL acute myeloid leukemia cells. Manipulation of H19 levels did not alter drug sensitivity in the studied cells.
The players
K562 cells
These cells serve as a standard laboratory model for studying myeloid leukemia in cancer research.
HEL AML cells
This is a human erythroleukemia cell line frequently used to model acute myeloid leukemia in laboratory experiments.
The details
Prolonged exposure to azacitidine generated resistant cell lines, which exhibited a reduced apoptotic response to the medication. Researchers utilized RNA sequencing to detect these specific lncRNA expression levels during the study.
Timeline
September 21, 2026: Article publication
The Big Picture
This study builds upon the existing knowledge regarding the development of azacitidine-resistant acute myeloid leukemia. By documenting H19 upregulation, the research adds to the growing field of epigenetic reprogramming in cancer therapy.
This research provides clinical insight into how leukemia cells adapt to common treatments, which may eventually lead to better monitoring of drug resistance in patients. Currently, these findings are confined to laboratory settings and do not impact immediate patient treatment protocols.
The takeaway
While H19 upregulation is a marker for drug-resistant leukemia cells, manipulating it alone does not restore sensitivity to azacitidine. Future research must look for other markers of epigenetic reprogramming to effectively overcome treatment resistance.
Further reading
Learn more about the latest research in the Cancer section.
More information
Access the complete findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
